Pfizer settles long-running Nigerian suit for $75M; Moody's rates HCA's debt offering as junk;

> Pfizer has finally dispatched a Nigerian lawsuit over tests of its drug Trovan which has dragged on for more than 10 years. The price: $75 million, including $30 million in healthcare initiatives, $10 million in legal costs and $35 million to study participants. Article

> Moody's Investors Service has assigned a Ba3 rating to HCA's planned $750 million debt offering, putting the chain's debt in junk-bond territory. FierceHealthFinance

> Consumers are getting psyched about the potential benefits of telemedicine, especially remote monitoring of their conditions through telemedical networks. FierceHealthIT

> Over the past three years, the U.S. military has deployed at least 200 robots to remote locations to assist Army doctors. FierceMobileHealthcare

And Finally... Hey, when I'm forced to take a walk on Boardwalk with four hotels on it, I get pretty upset, too. (Well, not that upset.) Article

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.